Potential

The team aims to provide patients who suffer from large and deep skin defects with the first personalized and automated skin tissue therapy that is safe, effective, and accessible for children and adults.

Project Description

After suffering a severe wound, human skin fails to regenerate and physiologically heals by scar formation. Worldwide, millions of people suffer from severe skin defects or diseases requiring surgical interventions to restore skin function.

Existing therapies frequently leave these patients with permanent, painful, disfiguring, and debilitating scars. Scars may impair movement and growth, and often require several follow-up surgeries, intense homecare, and psychosocial rehabilitation. Severe skin defects significantly affect quality of life in the long term and place an economic burden on the healthcare system. Human skin is composed of the epidermis, dermis, and hypodermis. The components of the dermis control and regulate scarring. Today’s standard of care consists in harvesting a thin layer of the patient’s healthy skin, which contains the epidermis but only remnants of the dermis. Since there is a lack of sufficient dermis significant dermis is missing, these grafts often develop into scars. Furthermore, in severe cases, in which most of the skin has been destroyed (e.g., severe burns), the shortage of healthy skin that can be harvested to cover the wounds presents a real clinical challenge.

In 2001 a team of University Children’s Hospital Zurich, led by Prof. M. Meuli, M.D., and Prof. E. Reichmann, M.D., pursued the vision of bio-engineering personalized dermo-epidermal skin grafts, using a small sample of patients’ own skin. One of the products they developed, denovoSkin, which is now in further development by CUTISS AG, is the result of more than fifteen years of research.

The project, led by Daniela Marino and Fabienne Hartmann-Fritsch, evolved from a promising research project of the University of Zurich and University Children's Hospital Zurich into the successful startup CUTISS AG, which has gained international recognition.

Contact

CUTISS AG
+41 44 244 36 60
info@cutiss.swiss

Faculty Mentor

Martin Meuli

Portrait denovo Skin mentor meuli 280

Faculty Mentor

Ernst Reichmann

Portrait denovo Skin mentor reichmann 264

Partners and Funding

Project Partners

  • University of Zurich, Tissue Biology Research Unit
  • University Children’s Hospital Zurich

Funding Partners

  • EU Horizon 2020
  • Innosuisse
  • Lichtsteiner Foundation
  • UZH Life Sciences Fund
  • W.A. De Vigier Foundation

Achievements

12/2024
Phase III clinical trial authorized

The European Medicines Agency has authorized Phase III clinical trial for CUTISS AG lead product, denovoSkin™. Read more.

05/2024
Closing Series C funding round with CHF 25M

CUTISS AG has successfully closed its first CHF 25M in its Series C funding round. Read more.

04/2023
Completion of Phase II clinical trial

CUTISS AG announces positive clinical trial results.  Read more.

02/2022
Wyss Zurich project completion

The project denovoSkin exits Wyss Zurich and continues operations in its startup company CUTISS AG.

01/2022
CUTISS AG opens subsidiary in France

The new subsidiary, CUTISS Innovation, will open in Europe’s leading technology park in France.

09/2021
Ranked 2nd at TOP 100 Swiss Startup Award 2021

CUTISS AG takes second place at the TOP 100 Swiss Startup Award 2021.

09/2020
Winner of TOP 100 Swiss Startup Award 2020

CUTISS AG wins the Top 100 Swiss Startup Award 2020, granted by a jury of 100 leading startup experts and investors.

06/2020
Closing Series B funding with CHF 20M

CUTISS AG successfully closed its series B financing round. The fundraising aiming at CHF 20M was eventually oversubscribed.

11/2019
Winner of Swiss Technology Award 2019

denovoSkin's startup company receives the prestigious Swiss Technology Award in the category Start-ups.

06/2018
Closing Series A funding with CHF 7.2M

CUTISS AG raises CHF 7.2M in a Series A financing round led by Giammaria Giuliani.

09/2017
Closing seed funding with CHF 1M

CUTISS AG raises CHF 1M in seed funding. The funds raised with UZH Life Sciences Fund investor will be used to launch the development of the automation of the production process for denovoSkin™.

05/2017
Winner of W.A. De Vigier Award 2017

CUTISS AG wins prestigious W.A. De Vigier Award 2017 and Audience Award.

03/2017
CUTISS AG incorporation

The UZH spin-off denovoSkin is incorporated under the name CUTISS AG. 

10/2016
Wyss Zurich admission

denovoSkin is accepted as full project at Wyss Zurich.

Founding Team

Daniela marino portrait

Daniela Marino

Co-Founder

Portrait denovo Skin mentor meuli 280

Martin Meuli

Co-Founder

Fabienne hartmann fritsch portrait

Fabienne Hartmann-Fritsch

Co-Founder

Portrait denovo Skin mentor reichmann 264

Ernst Reichmann

Co-Founder

Do you have a breakthrough project you want us to know about?

We invite you to contact the Wyss Zurich office to discuss your project and start the evaluation process.